Company intelligence / Profile preview

Taizhou Hanzhong Biopharma

Taizhou, Jiangsu, Chinaen.lepubiopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Taizhou Hanzhong Biopharma is an active Chinese biopharmaceutical company focused on oncology therapeutics. Its lead asset is pucotenlimab—a PD‑1 monoclonal antibody—which has reached Phase 3 development and received approval in China for certain indications. The company participates in the development of innovative biologics including monoclonal antibodies and oncolytic viruses through collaborations with partners such as Lepu Biopharma. It operates GMP-compliant manufacturing facilities supporting both clinical supply and commercial production.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyOncolytic virus therapyAntibody-drug conjugate
Industry: Biotech

Partnerships

Lepu Biopharma Co., Ltd.AkesoHanX Biopharma

Beyond the preview

Go deeper on Taizhou Hanzhong Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taizhou Hanzhong Biopharma.

Explore the full profile